iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/34185076
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 2;23(8):1231-1251.
doi: 10.1093/neuonc/noab106.

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N Louis  1 , Arie Perry  2 , Pieter Wesseling  3   4 , Daniel J Brat  5 , Ian A Cree  6 , Dominique Figarella-Branger  7 , Cynthia Hawkins  8 , H K Ng  9 , Stefan M Pfister  10 , Guido Reifenberger  11 , Riccardo Soffietti  12 , Andreas von Deimling  13   14 , David W Ellison  15
Affiliations
Review

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N Louis et al. Neuro Oncol. .

Abstract

The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.

Keywords: World Health Organization; brain tumor; central nervous system; classification; diagnosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a glial neoplasm associated with a history of epilepsy in young people, diffuse growth patterns, frequent presence of oligodendroglioma-like components, calcification, CD34 immunoreactivity, and MAPK pathway-activating genetic abnormalities. (A) Common oligodendroglioma-like appearance (H&E, ×200), but (B) histological appearances can vary greatly within tumors (H&E, ×400). (C) CD34 immunostaining is typically strong and diffuse in the tumor (×100); and (D) is often found in the peritumoral cortex (×200).
Fig. 2
Fig. 2
Diffuse hemispheric glioma, H3 G34-mutant, is a malignant, infiltrative glioma, typically of the cerebral hemispheres and with a missense mutation in the H3F3A gene that results in a G34R/V substitution of histone H3. (A) High-grade anaplastic features, sometimes with an embryonal appearance (H&E, ×200) and (B) positive nuclear staining with H3 G34R/V immunohistochemistry (×100).
Fig. 3
Fig. 3
Myxoid glioneuronal tumor is a tumor typically arising in the septal region and involving the lateral ventricle. It is characterized by a proliferation of oligodendrocyte-like tumor cells embedded in a prominent myxoid stroma, often including admixed floating neurons, neurocytic rosettes, and/or perivascular neuropil, and by a dinucleotide mutation in the PDGFRA gene. (A) Common septal location (magnetic resonance imaging, T1 with contrast) and (B) characteristic histological features with small round cells and myxoid stroma (H&E, ×200).
Fig. 4
Fig. 4
Multinodular and vacuolating neuronal tumor is a benign tumor comprising monomorphous neuronal elements in discrete and coalescent nodules, with vacuolar changes both in tumor cells and the neuropil. (A) Multinodular appearance (H&E, ×40). (B) Vacuolar change in tumor cells and in neuropil (H&E, ×200).
Fig. 5
Fig. 5
CNS tumor with BCOR internal tandem duplication is a neoplasm with a mostly solid growth pattern, uniform oval or spindle-shaped cells, a dense capillary network, focal pseudorosette formation, and an internal tandem duplication (ITD) in exon 15 of the BCOR gene. (A) High-grade neoplasm with perivascular rosettes (H&E, ×200) and (B) strong, diffuse nuclear staining on BCOR immunohistochemistry (×100).
Fig. 6
Fig. 6
Desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant is a rare pineal-region tumor that features desmoplasia and myxoid changes (H&E, ×200) (A) as well as loss of INI1 staining (×200) (B).
Fig. 7
Fig. 7
Newly recognized mesenchymal, non-meningothelial tumors of uncertain histogenesis. (A) Intracranial mesenchymal tumor, FET-CREB fusion-positive (H&E, ×200); these tumors have variable morphology and a fusion of an FET RNA-binding protein family gene and a member of the CREB family of transcription factors. (B, C) CIC-rearranged sarcoma, with (B) poorly differentiated cells (H&E, ×200) and (C) with ETV4 frequently being upregulated in these tumors (×200). (D) Primary intracranial sarcoma, DICER1-mutant with characteristic eosinophilic cytoplasmic droplets (H&E, ×200).
Fig. 8
Fig. 8
Pituitary blastoma is a malignant embryonal sellar neoplasm composed of primitive blastemal cells, neuroendocrine cells, and Rathke epithelium, typically occurring in young children and linked to germline or somatic variants in the DICER1 gene. (A) Neuroendocrine cells arranged in lobules, rosettes, and glands, interspersed with small undifferentiated, blastemal cells (H&E, ×100) and with (B) ACTH immunoreactivity in some cells (×200).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed.Lyon: International Agency for Research on Cancer; 2021.
    1. Zulch KJ. Histological Typing of Tumours of the Central Nervous System. Vol. 21. Geneva: World Health Organization; 1979.
    1. Kleihues P, Burger PC, Scheithauer BW.. Histological Typing of Tumours of the Central Nervous System. Berlin: Springer-Verlag; 1993.
    1. Kleihues P, Cavenee WK.. World Health Organization Classification of Tumours of the Nervous System. Lyon: WHO/IARC; 2000.
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK.. World Health Organization Histological Classification of Tumours of the Central Nervous System. 4th ed.Lyon: International Agency for Research on Cancer; 2007.